Sarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP has reduced its stake in Sarepta Therapeutics by 20%, selling 50,000 shares and retaining approximately 200,000 shares, valued at around $12.76 million.
• Sarepta Therapeutics recently reported a 68.4% increase in quarterly revenue, totaling $611.09 million, significantly exceeding analyst estimates.
• Analysts have mixed ratings on Sarepta's stock, with target prices ranging from $12.00 to $80.00, reflecting varied outlooks on its future performance.

Vestal Point Capital LP decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 200,000 shares of the biotechnology company's stock after selling 50,000 shares during the period. Vestal Point Capital LP owned approximately 0.20% of Sarepta Therapeutics worth $12,764,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SRPT. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $31,000. Pandora Wealth Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $45,000. Brooklyn Investment Group boosted its position in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock worth $46,000 after buying an additional 590 shares during the period. Finally, UMB Bank n.a. boosted its position in shares of Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after buying an additional 276 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analyst Ratings Changes

SRPT has been the subject of several analyst reports. Mizuho reaffirmed a "neutral" rating and issued a $14.00 target price (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Sanford C. Bernstein began coverage on Sarepta Therapeutics in a report on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 price target for the company. Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a report on Monday, July 28th. Bank of America increased their price target on Sarepta Therapeutics to $17.00 and gave the company an "underperform" rating in a report on Wednesday, August 20th. Finally, BMO Capital Markets increased their price target on Sarepta Therapeutics from $25.00 to $50.00 and gave the company a "market perform" rating in a report on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $43.50.

Sarepta Therapeutics Stock Up 1.4%

NASDAQ SRPT traded up $0.25 on Friday, hitting $18.71. 5,173,257 shares of the stock traded hands, compared to its average volume of 8,586,767. The stock has a 50-day moving average of $17.78 and a 200 day moving average of $43.48. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81. The company has a market capitalization of $1.83 billion, a P/E ratio of -21.51 and a beta of 0.49. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. During the same quarter in the prior year, the firm posted $0.07 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 68.4% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.